## Autơlus

## Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

October 25, 2021
LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021.

Management will host a conference call and webcast at $8: 30 \mathrm{am} \mathrm{ET} / 1: 30 \mathrm{pm}$ GMT to discuss the company's financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 6984737. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 6984737.

## Contact:

[^0]
[^0]:    Lucinda Crabtree, PhD
    Vice President, Business Strategy and Planning
    +44 (0) 7587372619
    I.crabtree@autolus.com

    Julia Wilson
    +44 (0) 7818430877
    iwilson@autolus.com
    Susan A. Noonan
    S.A. Noonan Communications
    +1-212-966-3650
    susan@sanoonan.com

